05:31 PM EDT, 08/29/2024 (MT Newswires) -- Artiva Biotherapeutics ( ARTV ) reported a Q2 loss late Thursday of $22 per diluted share, wider than a loss of $14.09 a year earlier.

Four analysts surveyed by Capital IQ expected a loss of $4.40.

No revenue for the quarter ended June 30 was reported. Revenue a year earlier was $3.5 million.

Four analysts polled by Capital IQ estimated $80,000.

As of June 30, the company said it had $46.6 million in cash, cash equivalents, and short-term investments. It said the $179 million in gross proceeds from its initial public offering in July extends cash runway at least through the end of 2026 and through key clinical data milestones.